RSX News Alert Russia ETF Market Vectors (RSX) 14.63 01/01/2015

New Post Public Reply Private Reply Replies (0) Message Board

Jan 1, 2015 at 4:41 PM

Russia ETF Market Vectors (RSX) 14.63 $RSX

Russia Experiences A Double Whammy As It Heads For A Recession
Sarfaraz A. Khan - at Seeking Alpha - Thu Jan 01, 7:32AM CST

RUSL: 16.54 (-3.51), RBL: 14.36 (-0.83), RUSS: 28.10 (+4.05), RSX: 14.63 (-0.91), BP: 38.12 (-0.24), ERUS: 11.47 (-0.73)

Opportunities In Russia?
Vulcan Investments - at Seeking Alpha - Wed Dec 31, 12:55PM CST

RSX: 14.63 (-0.91)

Interesting RSX Put And Call Options For February 2015
at The Street - Wed Dec 31, 10:25AM CST
Investors in Russia ETF saw new options begin trading today, for the February 2015 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the RSX options chain for the new February 2015 contracts and identified one put...
RSX: 14.63 (-0.91)

Best Of 2014: Economics, Capital Flows And Innovation
CFA Institute Contributors - at Seeking Alpha - Tue Dec 30, 4:04PM CST
By Ron Rimkus, CFA Every year at this time, we reflect back on the events of the last 12 months and take inventory. This year (2014) will likely go down in history as a pivotal transition year. The status quo is shifting. We are leaving...
USO: 20.36 (+0.07), VGK: 52.41 (-0.39), SPY: 205.54 (-2.06), QQQ: 103.25 (-1.07), FXY: 81.21 (-0.20), OIL: 12.54 (+0.04), DIA: 177.88 (-1.58), RSX: 14.63 (-0.91), EWJ: 11.24 (-0.06)

Market Vectors - Russia ETF Down 36.4% Since SmarTrend Downtrend Call (RSX)
Comtex SmarTrend(R) - Tue Dec 30, 9:45AM CST
SmarTrend identified a Downtrend for Market Vectors - Russia ETF (NYSE:RSX) on September 2nd, 2014 at $23.62. In approximately 4 months, Market Vectors - Russia ETF has returned 36.38% as of today's recent price of $15.03.
RSX: 14.63 (-0.91)

Top ETF Stories Of 2014 Worth Watching In 2015
Zacks Funds - Seeking Alpha - Mon Dec 29, 4:37PM CST
The stock market across the globe has given mixed performances in 2014. While the Dow Jones Industrial Average crossed the 18,000 mark for the first time in mid December and the S&P 500 is on the verge of crossing the 2,100 level on the back of...
USO: 20.36 (+0.07), IEF: 105.99 (+0.12), RSXJ: 19.85 (-0.43), OIH: 35.92 (-0.30), XOP: 47.86 (-0.09), RBL: 14.36 (-0.83), FCG: 11.21 (-0.04), BNO: 22.70 (+0.23), SHY: 84.45 (-0.03), RSX: 14.63 (-0.91), ERUS: 11.47 (-0.73), TLT: 125.92 (+0.24)

After Yesterday's Decline of 8.80%, Market Vectors - Russia ETF Offers Investors Better Value
Comtex SmarTrend(R) - Mon Dec 29, 3:39PM CST
Market Vectors - Russia ETF (NYSE:RSX) traded in a range yesterday that spanned from a low of $14.01 to a high of $15.58. Yesterday, the shares fell 8.8%, which took the trading range below the 3-day low of $15.24 on volume of 34.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
RSX: 14.63 (-0.91)

Market Vectors - Russia ETF Set to Possibly Rebound After Yesterday's Selloff of 8.80%
Comtex SmarTrend(R) - Mon Dec 29, 3:38PM CST
Market Vectors - Russia ETF (NYSE:RSX) traded in a range yesterday that spanned from a low of $14.01 to a high of $15.58. Yesterday, the shares fell 8.8%, which took the trading range below the 3-day low of $15.24 on volume of 34.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
RSX: 14.63 (-0.91)

Calvert Chief Investment Officer Natalie Trunow: 2015 GDP Up 3.5%, Stocks 5 - 10%
Harlan Levy - at Seeking Alpha - Mon Dec 29, 2:52PM CST

SPY: 205.54 (-2.06), IEV: 42.53 (-0.31), QQQ: 103.25 (-1.07), DIA: 177.88 (-1.58), RSX: 14.63 (-0.91), IWM: 119.62 (-0.72), EWJ: 11.24 (-0.06)

Putin Overestimates Russia's Economic Strength
Epoch Times - at Seeking Alpha - Mon Dec 29, 1:52PM CST
By Valentin Schmid [Originally published on 11/17/2014] In any kind of conflict, it’s always good to hear the other side. German TV station ARD gave Russian President Vladimir Putin 30 minutes of airtime Sunday. Apart from defending...
RSX: 14.63 (-0.91)

Top ETF Stories of 2014 Worth Watching in 2015 - ETF News And Commentary
Sweta Killa - ZACKS - Mon Dec 29, 12:00PM CST
These ETFs could be ones to watch heading into 2015.
USO: 20.36 (+0.07), IEF: 105.99 (+0.12), RSXJ: 19.85 (-0.43), OIH: 35.92 (-0.30), XOP: 47.86 (-0.09), FCG: 11.21 (-0.04), BNO: 22.70 (+0.23), SHY: 84.45 (-0.03), RSX: 14.63 (-0.91), ERUS: 11.47 (-0.73), TLT: 125.92 (+0.24)

Commodities Today: Icahn Strikes Again, Higher Margins For Shippers In 2015
Matthew Smith - at Seeking Alpha - Mon Dec 29, 11:23AM CST

FDX: 173.66 (-1.34), PBR: 7.30 (+0.03), PBR.A: 7.58 (+0.04), RSX: 14.63 (-0.91), MTW: 22.10 (-0.24), UPS: 111.17 (-0.97)

Canadian Dollar, Russian Rouble And Oil
Marc Chandler - Seeking Alpha - Mon Dec 29, 9:26AM CST
Over the past six months, the Canadian dollar has been the best performing of the major currencies against the US dollar . It has only lost about 8.3% against the greenback. On the other hand, the Russian rouble is the worst performing of...
OIL: 12.54 (+0.04), FXC: 85.54 (-0.13), RSX: 14.63 (-0.91)

Ruble weakens as Russian economy shrinks
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 8:30AM CST

RSXJ: 19.85 (-0.43), RUSL: 16.54 (-3.51), RBL: 14.36 (-0.83), RUSS: 28.10 (+4.05), RSX: 14.63 (-0.91), ERUS: 11.47 (-0.73)

Additional income distribution for Market Vectors Russia ETF for December 2014
M2 - Mon Dec 29, 3:49AM CST
The Market Vectors ETF Trust revealed on Saturday that it will pay an additional special income distribution of USD0.0230 per share for the exchange traded fund, Market Vectors Russia ETF (NYSEArca:RSX) for December 2014.
RSX: 14.63 (-0.91)

What Lies Behind The Plunge Of The Ruble?
Ed Dolan - at Seeking Alpha - Sun Dec 28, 11:54AM CST
Russia's economy is in trouble. Growth has come to a halt. A recession looms in 2015. Inflation, interest rates, and capital flight are up. The government's budget is under strain. More than any of these, what makes the headlines is the plunge of the...
RUSL: 16.54 (-3.51), RBL: 14.36 (-0.83), RUSS: 28.10 (+4.05), RSX: 14.63 (-0.91), ERUS: 11.47 (-0.73)

Monitoring Global Market Hot Zones
Eric Parnell, CFA - at Seeking Alpha - Sun Dec 28, 1:18AM CST

GREK: 13.40 (-0.03), RSX: 14.63 (-0.91), EMB: 109.71 (-0.85), NGE: 10.57 (-0.21)

December 2014 Additional Income Distribution for Market Vectors Russia ETF
Business Wire - Fri Dec 26, 5:55PM CST
The Market Vectors ETF Trust announced today the December 2014 additional income distribution per share for the Market Vectors Russia ETF.
RSX: 14.63 (-0.91)

Russia sees GDP falling 4% in 2015
Seeking Alpha - at Seeking Alpha - Fri Dec 26, 6:08AM CST

RSXJ: 19.85 (-0.43), RUSL: 16.54 (-3.51), RBL: 14.36 (-0.83), RUSS: 28.10 (+4.05), RSX: 14.63 (-0.91), ERUS: 11.47 (-0.73)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

ASTS Faces Crucial Deadline Amidst Legal Turmoil

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Pathalys' Phase 3 Data Shows Promise for CKD Drug

A Glimpse at Pathalys Pharma's Recent Win This is some groundbreaking stuff emerging from Pathalys Pharma. Their investigational drug, upacicalcet, has just clinched a significant victory in two crucial Phase 3 trials - PATH-1 and PATH-2 - aimed at treating Secondary Hyperparathyroidism (SHPT) in patients with end-stage kidney disease undergoing hemodialysis. With SHPT...

CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

World Young Scientist Summit 2026 in Wenzhou Kicks Off

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

DIRECTV Bags New NHL Deals: Stakes for Sports Fans

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

Apalutamide Boosts Outlook for Prostate Cancer Treatment

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

John Wong's Decade as Estate Planning Specialist

One man's legacy isn’t built overnight, especially not in estate planning. And John L. Wong's decade of being a certified specialist by the State Bar of California tells a story of perseverance and grit. Now, at the helm of Modern Wealth Law in Irvine, California, Wong is a name that echoes through the halls of estate planning law with authority and respect. Creating...

Bio-Thera's New Data: A Game Changer for NSCLC?

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...